137 related articles for article (PubMed ID: 36058306)
1. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity.
Tisminetzky M; Gurwitz JH; Tabada G; Reynolds K; Fortmann SP; Garcia E; Pham T; Goldberg R; Go AS
Am J Med; 2022 Dec; 135(12):1468-1477. PubMed ID: 36058306
[TBL] [Abstract][Full Text] [Related]
2. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
[TBL] [Abstract][Full Text] [Related]
3. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
4. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
[TBL] [Abstract][Full Text] [Related]
5. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
[TBL] [Abstract][Full Text] [Related]
7. Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study.
Mathieson L; Severn A; Guthrie B
Scott Med J; 2013 May; 58(2):69-76. PubMed ID: 23728750
[TBL] [Abstract][Full Text] [Related]
8. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.
Jun HR; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS
Cardiovasc Ther; 2021; 2021():5935149. PubMed ID: 33747123
[TBL] [Abstract][Full Text] [Related]
9. Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study.
Hines A; Li X; Ortiz-Soriano V; Saleh S; Litteral J; Ruiz-Conejo M; Wald R; Silver SA; Neyra JA
Am J Nephrol; 2020; 51(4):266-275. PubMed ID: 32088714
[TBL] [Abstract][Full Text] [Related]
10. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
[TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
[TBL] [Abstract][Full Text] [Related]
13. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
14. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
15. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
[TBL] [Abstract][Full Text] [Related]
16. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
18. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
Bertero E; Miceli R; Lorenzoni A; Balbi M; Ghigliotti G; Chiarella F; Brunelli C; Viazzi F; Pontremoli R; Canepa M; Ameri P
Intern Emerg Med; 2019 Oct; 14(7):1083-1090. PubMed ID: 30835055
[TBL] [Abstract][Full Text] [Related]
19. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
20. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery.
Coca SG; Garg AX; Swaminathan M; Garwood S; Hong K; Thiessen-Philbrook H; Passik C; Koyner JL; Parikh CR;
Nephrol Dial Transplant; 2013 Nov; 28(11):2787-99. PubMed ID: 24081864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
